Skip to content

Intracoronary Application of Combining Thrombus Aspiration and Recombinant Human Prourokinase on the Coronary Flow during Primary PCI for the Acute Myocardial Infarction

A Randomized, Parallel-controlled, Multi-center Trial for the Effects of Intracoronary Application of Combining Thrombus Aspiration and Recombinant Human Prourokinase on the Coronary Flow during Primary PCI for the Acute Myocardial Infarction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022666
Enrollment
Unknown
Registered
2019-04-21
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Interventions

experimental group 1:intracoronary injection of rh-proUK+ thrombus aspiration+PCI
experimental group 2: thrombus aspiration+intracoronary injection of rh-proUK+PCI
control group:thrombus aspiration+PCI

Sponsors

Hu'nan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.The patient was diagnosed as ST-segment elevation myocardial infarction and symptoms onset less than 12h; 2. Aged 18 to 75 yeas old; 3. Coronary angiography showed the TIMI thrombus grade=2.

Exclusion criteria

Exclusion criteria: (1) Patients with rescue PCI who have undergone intravenous thrombolysis; (2) History of intracranial hemorrhage; (3) Ischemic stroke within 3 months; (4) Suspicious aortic dissection; (5) Active bleeding (including menstruation); (6) Severe head or face injuries within 3 months; (7) Severe or uncontrolled high blood pressure (SBP>180mmHg or DBP>110mmHg); (8) Severe trauma, major surgery or unoppressible vascular bleeding within 3 weeks; (9) Malignant tumors or patients with life expectancy less than half a year; (10) Severe liver or kidney dysfunction; (11) History of hematologic diseases or oral warfarin recently; (12) Pregnant women, lactating women or women who may become pregnant; (13) It is known that there is a contraindication to the study drug or contrast agent; (14) Patients who have undergone coronary artery bypass grafting; (15) Patients have participated in other clinical studies at the same time; (16) Thrombus aspiration catheter cannot pass through the lesion of the criminal vessel.

Design outcomes

Primary

MeasureTime frame
Corrected TIMI frame count;

Secondary

MeasureTime frame
TIMI blood flow grading;TIMI myocardial perfusion grade;Myocardial Blush Grades;TIMI thrombosis grading;ST-segment resolution in 1h after PCI;

Countries

China

Contacts

Public ContactPan Hongwei

Hu'nan Provincial People's Hospital

panhongweihnsry@163.com+86 13487311869

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026